
TROPiCS-03 (IMMU-132-11) Study:



A Phase 2 Open-Label Study of Sacituzumab Govitecan in Subjects with Metastatic Solid Tumors



- Female or male patients ≥18 years of age
- ECOG PS of 0 or 1
- Documented metastatic or locally advanced solid tumors (NSCLC, HNSCC, endometrial, and SCLC)
- Measurable disease by CT or MRI as per RECIST v1.1
- Adequate hepatic and renal function (CrCl ≥30mL/min)
- Adequate hematologic counts without transfusion or growth factor support within 2 weeks of study drug initiation

Questions?

For more information on the TROPiCS-03 Study, please contact GileadClinicalTrials@gilead.com

Safety and efficacy have not been demonstrated for the investigational uses described here. There is no guarantee that the investigational therapies or uses will be approved for use. Visit clinicaltrials.gov for more information. Clinicaltrials.gov: NCT03964727

ADA, anti-drug antibodies; BICR, blinded independent central review; CBR, clinical benefit rate; CrCl, creatinine clearance; CT, computed tomography; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HNSCC, head and neck squamous cell carcinoma; IO, immuno-oncology; IV, intravenous; m, metastatic; MRI, magnetic resonance imaging; NSCLC, non-small cell lung carcinoma; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PK, pharmacokinetics;

POC, proof of concept; RECIST v 1.1, Response Evaluation Criteria in Solid Tumors Version 1.1; SCLC, small cell lung cancer; SCC, squamous cell carcinoma; s/p, status post.

References:

National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT03964727. Accessed January 24, 2022. Gilead Sciences Data on File.

Oncology

GILEAD